Tom Coulter, PhD, is a drug discovery strategist and operator focused on translating early-stage science into investable opportunities.

WIth a background spanning pharma, biotech and contract research he brings diverse insights into drug discovery planning and execution.

Over more than 25 years he has built his career at the interface of discovery biology, CRO-enabled execution, and asset strategy, working on and directing multiple small molecule programmes from target evaluation through to development positioning. His experience spans hands-on delivery within contract research organisations and strategic roles shaping outsourced R&D models for biotech and pharma clients.

Tom works with investors, founders, and research teams to clarify scientific positioning, define executable development strategies, and to structure programmes for partnering, financing, or new company formation. He brings a practical understanding of how to move assets forward efficiently—aligning scientific ambition with capital discipline.

Through Causeway Bio, he focuses on supporting venture creation around high-potential discovery-stage assets and enabling lean, execution-focused paths to value inflection.